HCW Biologics Inc. Common Stock (HCWB)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach HCW Biologics as a speculative clinical-stage biotech, not a durable business. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $121,730 and a net loss of $5.2M, with diluted EPS of -$11.58. Fiscal Q1 2026, ended 2026-03-31, showed revenue of $6.5M and net income of $3.5M, but that looks like an event-driven anomaly rather than recurring operations. FY2025, ended 2025-12-31, had revenue of $54,232 and a net loss of $8.0M; FY2024 had revenue of $2.6M and a net loss of $30.0M; FY2023 had revenue of $2.8M and a net loss of $25.0M. The Lynch category is 'none' because it has lost money in each of the last four years. Financial health is poor. Trailing free cash flow was -$12.1M, a FairStock FCF yield of -524.5%, and FairStock's Piotroski score was 1/9 and Altman Z-score was -6.86. ROE was -151.36% and ROCE -13.88%, with D/E 0.88. At the 2026-10-13 close of $1.26, FairStock's P/B was 0.25, which might suggest asset cheapness, but the assets are being consumed by losses. The P/E of -0.08 reflects negative earnings, not value. Moat? I see none yet. It is a 35-employee company with early-stage immunotherapies; the value depends on clinical success and financing. Growth is erratic. I would want evidence of durable revenue, cash runway, and trial progress before treating this as an investment-grade business. Without that, the low price is a speculation, not a margin of safety.

In plain English: HCW Biologics is a very small clinical-stage biotech trying to develop new immune therapies for chronic inflammation and related diseases. The business looks weak because it has no profits, loses money, and burns cash, even though it sometimes reports revenue from collaborations. At $1.26, the price may look low compared with its accounting value, but the losses mean it is hard to call the stock cheap in a normal business sense.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer